IDEXX Laboratories Inc.
IDXX | NASDAQ
$516.64
+$4.99 (+0.98%)
Sep 21, 2026, 1:39 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 4.3B | 3.9B | 3.66B | 3.37B | 3.22B | 2.71B |
Cost of Revenue | 1.64B | 1.52B | 1.47B | 1.36B | 1.33B | 1.14B |
Gross Profit | 2.66B | 2.38B | 2.19B | 2B | 1.89B | 1.57B |
Operating Income | 1.36B | 1.13B | 1.1B | 898.77M | 932.03M | 694.52M |
Interest Income | 2.42M | 12.7M | 5.63M | 1.07M | 434K | 586K |
Pretax Income | 1.32B | 1.11B | 1.06B | 859.97M | 902.65M | 661.99M |
Net Income | 1.06B | 887.87M | 845.04M | 679.09M | 744.85M | 581.78M |
Selling & General & Admin | 1.05B | 1.03B | 901.89M | 850.75M | 796.4M | 735.27M |
Research & Development | 251.21M | 219.79M | 190.95M | 254.82M | 161.01M | 141.25M |
Other Expenses | n/a | n/a | n/a | 2.2M | 1.46M | n/a |
Operating Expenses | 1.3B | 1.25B | 1.09B | 1.11B | 957.4M | 876.52M |
Interest Expense | 38.27M | 31.21M | 41.58M | 39.86M | 29.81M | 33.13M |
Selling & Marketing Expenses | 643.55M | 588.51M | 566.07M | 524.51M | 486.74M | 434.44M |
Cost & Expenses | 2.94B | 2.77B | 2.56B | 2.47B | 2.28B | 2.01B |
Income Tax Expense | 264.73M | 221.96M | 216.13M | 180.88M | 157.81M | 79.85M |
Shares Outstanding (Basic) | 80.1M | 82.47M | 83.07M | 83.62M | 85.2M | 85.34M |
Shares Outstanding (Diluted) | 80.68M | 83.25M | 83.98M | 84.6M | 86.57M | 86.72M |
EPS (Basic) | 13.17 | 10.77 | 10.17 | 8.12 | 8.74 | 6.82 |
EPS (Diluted) | 13.08 | 10.67 | 10.06 | 8.03 | 8.60 | 6.71 |
EBITDA | 1.47B | 1.28B | 1.22B | 1.01B | 1.04B | 793.81M |
EBIT | 1.36B | 1.14B | 1.1B | 899.83M | 932.46M | 695.11M |
Depreciation & Amortization | 106.46M | 129.94M | 114.91M | 111.9M | 104.6M | 96M |
Add to Watchlist
Select watchlists to add or remove IDXX